Home| Features| About| Customer Support| Request Demo| Our Analysts| Login
Gallery inside!
Markets

Vir Biotechnology, Walmart, Home Depot, and more stocks making premarket moves

February 21, 2023
minute read

In premarket trading, here are the biggest moves:

‍

Walmart

Shares of Walmart fell roughly 4% before the bell after Walmart shared a cautious outlook for 2014. Consumers are trading down and purchasing fewer discretionary items than last year. Despite beating holiday quarter sales and bottom-line expectations, the retail giant's shares still rose.

‍

Home Depot

After Home Depot reported weaker-than-anticipated sales for the fourth quarter, the retail stock fell 4% in premarket trade. Home Depot reported $35.83 billion in sales and $3.30 in earnings per share. Refinitiv's survey of analysts revealed that they anticipated earnings of $3.28 per share on $35.97 billion in revenue. Home Depot also stated that it anticipated flat sales for the upcoming fiscal year.

‍

Vir Biotechnology

As a result of Goldman Sachs' upgrade to buy from neutral, the immunology company rose nearly 11%. In the year ahead, Vir is expected to release data on its flu vaccine, according to Trade Algo analysts.

‍

AutoNation

JPMorgan downgraded the dealer from neutral to underweight, resulting in a 2.1% drop. A pullback in consumer demand for vehicles is making the company appear overvalued, according to analyst Rajat Gupta.

‍

HSBC Holdings

Earnings for the fourth quarter of the bank exceeded expectations, leading to a gain of approximately 4%. In its report, HSBC noted that revenues and operating expenses were both higher than expected.

‍

Medtronic

After it reported adjusted earnings per share of $1.30, overtaking StreetAccount's expectations of $1.27, the healthcare technology company rose 2.3%. Sales exceeded expectations as well.

‍

General Mills

Support for consumer demand lifted General Mills' full-year forecast before the bell, citing strong sales of Cheerios.

‍

Generac Holdings

Following Truist's downgrade to hold from buy, shares slid more than 2%. Wall Street analysts cited Generac's 2023 financials as being at risk from high-interest rates and higher product prices.

Tags:
Author
Adan Harris
Managing Editor
Eric Ng
Contributor
John Liu
Contributor
Editorial Board
Contributor
Bryan Curtis
Contributor
Adan Harris
Managing Editor
Cathy Hills
Associate Editor

Subscribe to our newsletter!

As a leading independent research provider, TradeAlgo keeps you connected from anywhere.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Explore
‍Related posts.